Study details
Enrolling now
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C)
Ivan de Kouchkovsky, MD
NCT IDNCT04346225ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
75
Study length
about 6.4 years
Ages
18+
Sex
Male only
Locations
1 site in CA
About this study
Researchers are testing whether hyperpolarized C-13 pyruvate MRI can help diagnose and monitor advanced prostate cancer. The trial will involve men with advanced prostate cancer who are receiving treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Hyperpolarized C13
- 2.Undergo Magnetic Resonance Imaging (MRI)
PhasePhase 2
Primary goalMean percent change from baseline in intra-tumoral kPG within target lesion after treatment
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Mean percent change from baseline in intra-tumoral kPG within target lesion after treatment., Mean percent change from baseline in intra-tumoral kPL within target lesion after treatment. (Cohort B)
Procedures
imaging
Body systems
Oncology